CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

Application Number 89488

Trade Name Diphenhydramine Hydrochloride Capsules USP 25mg

Generic Name Diphenhydramine Hydrochloride Capsules USP 25mg

Sponsor Mutual Pharmaceutical Co, Inc.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION 89488

CONTENTS

	Included	Pending Completion	Not Prepared	Not Required
Approval Letter	X			
Tenative Approval Letter				
Approvable Letter				
Final Printed Labeling	X			
Medical Review(s)				
Chemistry Review(s)	X			
EA/FONSI				
Pharmacology Review(s)				
Statistical Review(s)				
Microbiology Review(s)				
Clinical Pharmacology Biopharmaceutics Review(s)				
Bioequivalence Review(s)	X			
Administrative Document(s)	X			
Correspondence	X			

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number 89488

APPROVAL LETTER

ANDA 89-488

Mutual Pharmaceutical Company, Inc.
Attention: Mr. Sulas Sardesai
1100 Orthocox Street
Philadelphia, Pennsylvania 19124

JAN 2 1987

Dear Mr. Sardesai:

Reference is made to your abbreviated new drug application submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for Diphenhydramine Hydrochloride Capsules USP, 25 mg.

Also referenced is your communication of November 21, 1986.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved.

Any significant change in the conditions outlined in this abbreviated application requires an approved supplemental application before the change may be made, except for changes made in conformance with other provisions of Section 314.70 of the New Drug Regulations.

Postmarketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80 and 314.81 of the Regulations.

This Administration should be advised of any change in the marketing status of this drug.

For Initial Campaigns: We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your immediate advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Advertising and Labeling (HFN-240). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

For Subsequent Campaigns. We call your attention to Section 314.81(b)(3) of the Regulations which requires that materials for any subsequent advertising or promotional campaign, at the time of their initial use, be submitted to our Division of Drug Advertising and Labeling (HFN-240) with a completed Form FD-2253.

cc:
HFN-237
TPoux/LChang/MGoldman
ved 12/18/86 (1516v)
APPROVAL

12/18/86
12/18/86
1-2-18-86

Sincerely yours,

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics

1/2/87

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 89488

FINAL PRINTED LABELING

Mutual Pharmaceutical Company, Inc.

1100 Orthodox Street • Philadelphia, Pennsylvania 19124 • (215) 288-6500

Each Capsule Contains:
Diphenhydramine HCl, USP ..... 25 mg

Dispense in tight container as defined in the USP.

Store at controlled room temperature
15°-30°C (59°-86°F)

Imprinted MUTUAL
103

NDC 53489-113-10

DIPHENHYDRAMINE HCl CAPSULES, USP 25 mg.

CAUTION: Federal law prohibits dispensing without prescription.

1000 CAPSULES

MUTUAL PHARMACEUTICAL CO., INC.
PHILADELPHIA, PA. 19124

Usual Dosage: see package insert

Lot No.:

Exp. Date:

12/13/88

Each Capsule Contains:
Diphenhydramine HCl, USP .....

Dispense in tight container as define

Store at controlled room temp
15°-30°C (59°-86°F)

Imprinted MUTUAL
103

NDC 53489-113-10

DIPHENHYDRAMINE HCl CAPSULES, USP 25 mg.

CAUTION: Federal law prohibits dispensing without prescription

1000 CAPSULES

Usage: see package insert

12/18/88

Each Capsule Contains
Diphenhydramine HCl, USP ..... 25 mg

Dispense in tight container as defined in the USP

Store at controlled room temperature
15°-30°C (59°-86°F)

Imprinted MUTUAL
103

NDC 53489-113-10

DIPHENHYDRAMINE HCl CAPSULES, USP 25 mg.

CAUTION: Federal law prohibits dispensing without prescription

1000 CAPSULES

MUTUAL PHARMACEUTICAL CO., INC.
PHILADELPHIA, PA. 19124

Usual Dosage: see package insert

Lot No.:

Exp. Date:

12/18/88

Mutual Pharmaceutical Company, Inc.

1100 Orthodox Street • Philadelphia, Pennsylvania 19124 • (215) 288-6500

Labeling: ORIGINAL

NDA No: [illegible] Rec'd. [illegible]

Reviewed by: _____







DOSAGE AND ADMINISTRATION: DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours.

ADULTS: 25 to 50 mg three to four times daily. The nighttime sleep-aid dosage is 50 mg at bedtime.

CHILDREN: (over 20 lb): 12.5 to 25 mg three or four times daily. Maximum daily dosage not to exceed 300 mg. For physicians who wish to calculate the dose on the basis of body weight or surface area, the recommended dosage is 5mg/kg/24 hours or 150 mg/m²/24 hours.

Data are not available on the use of diphenhydramine hydrochloride as a nighttime sleep-aid in children under 12 years.

The basis for determining the most effective dosage regimen will be the response of the patient to medication and the condition under treatment.

In motion sickness, full dosage is recommended for prophylactic use, the first dose to be given 30 minutes before exposure to motion and similar doses before meals and upon retiring for the duration of exposure.

HOW SUPPLIED

DIPHENHYDRAMINE HYDROCHLORIDE Capsules are supplied as follows:

DIPHENHYDRAMINE HYDROCHLORIDE 25 mg Pink/Clear capsules, Imprinted MUTUAL 103.

Bottles of 100, NDC 53489-113-01
Bottles of 1000, NDC 53489-113-10

DIPHENHYDRAMINE HYDROCHLORIDE 50 mg Pink/Pink capsules, Imprinted MUTUAL 107.

Bottles of 100, NDC 53489-114-01
Bottles of 1000, NDC 53489-114-10

STORAGE CONDITIONS: Store at controlled room temperature 15°-30°C (59°-86°F). Protect from moisture.

Caution — Federal law prohibits dispensing without prescription.

Manufactured by:
MUTUAL PHARMACEUTICAL COMPANY, INC.
Philadelphia, PA 19124

Issued: August 1986

DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES, USP

DESCRIPTION: Diphenhydramine hydrochloride is an antihistamine drug having the chemical name 2-(Diphenylmethoxy)-*N,N*-dimethylethylamine hydrochloride and has the empirical formula $C_{17}H_{21}NO{\cdot}HCl$ (molecular weight 291.82). It occurs as a white, crystalline powder and is freely soluble in water and alcohol. The structural formula is as follows:



Each diphenhydramine hydrochloride capsule contains 25 mg or 50 mg diphenhydramine hydrochloride for oral administration.

CLINICAL PHARMACOLOGY: Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.

A single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. The duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours. Diphenhydramine is widely distributed throughout the body, including the CNS. Little, if any, is excreted unchanged in the urine; most appears as the degradation products of metabolic transformation in the liver, which are almost completely excreted within 24 hours.

INDICATIONS AND USAGE: Diphenhydramine hydrochloride in the oral form is effective for the following indications:

Antihistaminic: For allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Motion sickness: For active and prophylactic treatment of motion sickness.

Antiparkinsonism: For parkinsonism (including drug-induced) in the elderly

unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents.

Nighttime sleep-aid.

CONTRAINDICATIONS

Use in Newborn or Premature Infants: This drug should not be used in newborn or premature infants.

Use in Nursing Mothers: Because of the higher risk of antihistamines for infants generally, and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

Antihistamines are also contraindicated in the following conditions:
Hypersensitivity to diphenhydramine hydrochloride and other anti-histamines of similar chemical structure.

WARNINGS: Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction.

Use in Children: In infants and children, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death.

As in adults, antihistamines may diminish mental alertness in children. In the young child, particularly, they may produce excitation.

Use in the Elderly (approximately 60 years or older). Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.

PRECAUTIONS:

General: Diphenhydramine hydrochloride has an atropine-like action and therefore should be used with caution in patients with a history of lower respiratory disease including asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension.

Information for Patients: Patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol.

Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.

Drug Interactions: Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.

Pregnancy: Pregnancy Category B. Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

ADVERSE REACTIONS: The most frequent adverse reactions are underscored.

1. *General:* Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose, and throat
2. *Cardiovascular System:* Hypotension, headache, palpitations, tachycardia, extrasystoles
3. *Hematologic System:* Hemolytic anemia, thrombocytopenia, agranulocytosis
4. *Nervous System:* Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions
5. *GI System:* Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation
6. *GU System:* Urinary frequency, difficult urination, urinary retention, early menses
7. *Respiratory System:* Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness

OVERDOSAGE: Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in children. Atropine-like signs and symptoms, dry mouth; fixed, dilated pupils; flushing, and gastrointestinal symptoms may also occur.

If vomiting has not occurred spontaneously the patient should be induced to vomit. This is best done by having him drink a glass of water or milk after which he should be made to gag. Precautions against aspiration must be taken, especially in infants and children.

If vomiting is unsuccessful gastric lavage is indicated within 3 hours after ingestion and even later if large amounts of milk or cream were given beforehand. Isotonic or 1/2 isotonic saline is the lavage solution of choice.

Saline cathartics, as milk of magnesia, by osmosis draw water into the bowel and therefore are valuable for their action in rapid dilution of bowel content.

Stimulants should not be used.

Vasopressors may be used to treat hypotension.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 89488

CHEMISTRY REVIEW(S)

CHEMIST'S REVIEW ANDA 89-488

3. NAME AND ADDRESS OF APPLICANT

Mutual Pharmaceutical Company, Inc.
Philadelphia, PA 19124

7. NONPROPRIETARY NAME

Diphenhydramine Hydrochloride

10. PHARMACOLOGICAL CATEGORY

Antihistamine

11. HOW DISPENSED

Rx

12. RELATED IND/NDA/DMF(s)

89-488 (25 mg)
89-489 (50 mg)

13. DOSAGE FORM(s)

Capsule

14. POTENCY

25 mg

15. CHEMICAL NAME AND STRUCTURE

Name and structure same as USP XXI

17. COMMENTS

18. CONCLUSIONS AND RECOMMENDATIONS

Approvable

19. REVIEWER:

MGoldman

DATE COMPLETED:

12/17/86

12/18/86

CHEMIST'S REVIEW ANDA 89-488

3. NAME AND ADDRESS OF APPLICANT

Mutual Pharmaceutical Company, Inc.
Philadelphia, PA 19124

7. NONPROPRIETARY NAME

Diphenhydramine Hydrochloride

10. PHARMACOLOGICAL CATEGORY

Antihistamine

11. HOW DISPENSED

Rx

12. RELATED IND/NDA/DMF(s)

89-488 (25 mg)
89-489 (50 mg)

13. DOSAGE FORM(s)

Capsule

14. POTENCY

25 mg

15. CHEMICAL NAME AND STRUCTURE

Name and structure same as USP XXI.

17. COMMENTS

18. CONCLUSIONS AND RECOMMENDATIONS

Not Approvable

19. REVIEWER:

MGoldman

DATE COMPLETED:

1c 130/88

CHEMIST'S REVIEW ANDA 89-488

3. NAME AND ADDRESS OF APPLICANT

Mutual Pharmaceutical Company, Inc.
Philadelphia, PA 19124

7. NONPROPRIETARY NAME

Diphenhydramine Hydrochloride

10. PHARMACOLOGICAL CATEGORY

Antihistamine

11. HOW DISPENSED

Rx

12. RELATED IND/NDA/DMF(s)

89-488 (25 mg)
89-489 (50 mg)

13. DOSAGE FORM(s)

Capsule

14. POTENCY

25 mg

15. CHEMICAL NAME AND STRUCTURE

Name and structure same as USP XXI (need italics for -N-N-).

17. COMMENTS

18. CONCLUSIONS AND RECOMMENDATIONS

Not Approvable

19. REVIEWER:

MGoldman

DATE COMPLETED:

10/8/86

20. COMPONENTS AND COMPOSITION

Component	Reference	mg/capsule
Diphenhydramine HCl	USP	25.0
Starch, NF	NF	
Magnesium Stearate	NF	
	TOTAL	160.0 mg

Components of capsule not given. See page 97.

CHEMIST'S REVIEW ANDA 89-488

3. NAME AND ADDRESS OF APPLICANT

Mutual Pharmaceutical Company, Inc.
Philadelphia, PA 19124

7. NONPROPRIETARY NAME

Diphenhydramine Hydrochloride

10. PHARMACOLOGICAL CATEGORY

Antihistamine

11. HOW DISPENSED

Rx

12. RELATED IND/NDA/DMF(s)

89-488 (25 mg)
89-489 (50 mg)

13. DOSAGE FORM(s)

Capsule

14. POTENCY

25 mg

15. CHEMICAL NAME AND STRUCTURE

Name and structure same as USP XXI (need italics for -N-N-).

17. COMMENTS

18. CONCLUSIONS AND RECOMMENDATIONS

Not Approvable

19. REVIEWER:

MGoldman

DATE COMPLETED:

9/11/86

9/17/86

20. COMPONENTS AND COMPOSITION

Component	Reference	mg/capsule
Diphenhydramine HCl	USP	25.0
Starch, NF	NF	
Magnesium Stearate	NF	
	TOTAL	160.0 mg

Components of capsule not given. See page 97.
Botanical source of Starch not given.

CHEMIST'S REVIEW ANDA 89-488

3. NAME AND ADDRESS OF APPLICANT

Mutual Pharmaceutical Company, Inc.
Philadelphia, PA 19124

7. NONPROPRIETARY NAME

Diphenhydramine Hydrochloride

10. PHARMACOLOGICAL CATEGORY — 11. HOW DISPENSED

Antihystamine — Rx

12. RELATED IND/NDA/DMF(s)

89-488 (25 mg)
89-489 (50 mg)

13. DOSAGE FORM(s) — 14. POTENCY

Capsule — 25 mg

15. CHEMICAL NAME AND STRUCTURE

Name and structure same as USP XXI (need italics for -N-N-).

17. COMMENTS

18. CONCLUSIONS AND RECOMMENDATIONS

Not Approvable

19. REVIEWER: — DATE COMPLETED:

MGoldman — 7/29/86

20. COMPONENTS AND COMPOSITION

Component	Reference
Diphenhydramine HCl	USP
Starch, NF	NF
Magnesium Stearate	NF

Components of capsule not given. See page 97.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 89488

BIOEQUIVALENCE REVIEW(S)

NDA 89-408
89-489

Mutual Pharmaceutical Co. Inc.
Attention: Suhas Sardesai
1100 Orthodox Street
Philadelphia, PA 19124

Dear Sir:

Reference is made to the dissolution data and request for waiver of in-vivo bioavailability requirements you submitted on May 9, 1986 for Diphenhydramine Hydrochloride Capsules, 25 mg.

The data and your request have been reviewed by our Division of Bioequivalence and they have the following comments:

"1. The dissolution testing conducted by Mutual Pharmaceutical Co. Inc. on its Diphenhydramine HCl Capsules, 25 mg and 50 mg, is acceptable. The waiver of the in-vivo bioequivalence study requirements for the 25 mg and 50 mg Diphenhydramine HCl Capsule is granted. The 25 mg and 50 mg capsule of the test product is therefore deemed bioequivalent to the 25 mg and 50 mg capsule, respectively, of Benadryl, manufactured by Parke-Davis Co.

2. The dissolution testing should be incorporated into your manufacturing controls and stability program. The dissolution testing should be conducted in 500 ml. of water @ 37°C using U.S.P. XXI Apparatus I (Basket) at 100 rpm. The test product should meet the following specification:

Not less than of the labeled amount of the drug in the dosage form is dissolved in 45 minutes."

Sincerely yours,

Marvin Seife 12/2/86

Marvin Seife, Ph.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics

cc: HFN-230
Goldman
MSeife/wsturm/jt/12-2-86
BIO 0530b

11/24/86

Diphenhydramine HCl
25 mg. Capsules
ANDA #89-488
Reviewer: Ramona D. McCarthy
Wang #8981e

Mutual Pharmaceutical Co, Inc.
Philadelphia, Pennsylvania
Submission Dated:
May 9, 1986

Review of Dissolution Data and a Request For A Waiver of The In-Vivo Bioequivalence Requirement

The firm submitted comparative dissolution data on both the test product and the reference product, Benadryl (diphenhydramine HCl) Capsules, 25 mg. The data demonstrate that the product meets our specifications of N.L.T. of the drug in the dosage form dissolved in 45 minutes.

This submission also contains a request for a waiver of the in-vivo bioequivalence requirement for this product.

The composition of this product is as follows:

Component	mg/Capsule
Diphenhydramine HCl, U.S.P.	25.0
Starch, N.F.	
Magnesium Stearate, N.F.	

Comment

In as much as the reference product Benadryl (diphenhydramine HCl) has been determined to be effective for at least one indication in a D.E.S.I. notice and this product is basically the same product, this product meets the criteria necessary to meet the requirements of C.F.R. 320.22(C)(1). Accordingly, a waiver may be granted and the firm should be so advised.

Recommendation

The firm should be advised as follows:

1. The dissolution testing conducted by Mutual Pharmaceutical Co. Inc. on its Diphenhydramine HCl Capsules, 25 mg., Lot #10069, is acceptable. The waiver of the in-vivo bioequivalence study requirements for the 25 mg. Diphenhydramine HCl Capsule is granted. The 25 mg. capsule of the test product is therefore deemed bioequivalent to the 25 mg. capsule of Benadryl, manufactured by Parke-Davis Co.

2. The dissolution testing should be incorporated into the firm's manufacturing controls and stability program. The dissolution testing should be conducted in 500 ml. of water @ 37°C using U.S.P. XXI Apparatus I (Basket) at 100 rpm. The test product should meet the following specification:

> Not less than of the labeled amount of the drug in the dosage form is dissolved in 45 minutes.

Ramona D. McCarthy
Division of Bioequivalence
Review Branch 1

RD INITIALED BY AJACKSON
FT INITIALED BY AJACKSON

Concur. _____ Date: 11-21-86
S.V. Dighe
Director
Division of Bioequivalence

R.McCarthy/do/11-10-86/Wang #8981e

cc: ANDA #89-488 original (2) HFN-230, HFN-200 (Hare), HFN-223 (Shah), HFN-252 (McCarthy, Jackson), Drug File

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 89488

CORRESPONDENCE

ANDA 89-488

Mutual Pharmaceutical Company, Inc.
Attention: Suhas Sardesai
1100 Orthodox Street
Philadelphia, PA 19124

NOV 3 1986

Dear Mr. Sardesai:

Please refer to your abbreviated new drug application dated May 9, 1986, submitted pursuant to Section 505 of the Federal Food, Drug, and Cosmetic Act for Diphenhydramine Hydrochloride Capsules USP, 25 mg.

Also referenced is your communication of October 14, 1986.

The application is deficient and therefore not approvable under Section 505 of the Act for the following reasons:

1. Your comparative dissolution rate studies and request for bioavailability/bioequivalency waiver is under review by the Division of Bioequivalence. You will be advised when their review is completed.

2. For the Components and Composition sections:

   21 CFR 314.50(d)(ii) Drug Product requires that you provide "A list of all components used in the manufacture of the drug product (regardless of whether they appear in the drug product); and a statement of the composition of the drug product. . ." You must submit a revised Component Section 6 and revised Composition Section 7 which lists all ingredients of the drug products, including the capsule. The container need not be included.

3. We acknowledge withdrawal of
   as a testing laboratory.

The file is now closed. You are required to take one of the actions described at 21 CFR 314.120 which will either amend or withdraw the application, or if you have substantial disagreement with our reasons for not approving this application, you may request an opportunity for a hearing.

Sincerely yours,

for 11-3-86

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics

10/30/86

cc:
HFN-237 10/30/86
TPoux/CChang/MGoldman/tr/10/30/86
1032S
Not Approvable 10-30-86

ANDA 89-488

Mutual Pharmaceutical Company, Inc.
Attention: Suhas Sardesai
1100 Orthodox Street
Philadelphia, PA 19124

Dear Mr. Sardesai:

Please refer to your abbreviated new drug application dated May 9, 1986, submitted pursuant to Section 505 of the Federal Food, Drug, and Cosmetic Act for Diphenhydramine Hydrochloride Capsules USP, 25 mg.

Also referenced is your communication of September 19, 1986.

The application is deficient and therefore not approvable under Section 505 of the Act for the following reasons:

1. Your comparative dissolution rate studies and request for bioavailability/bioequivalency waiver is under review by the Division of Bioequivalence. You will be advised when their review is completed.

2. For the Components and Composition sections:

   You must provide a copy of your revised Component section and your revised Composition section showing the formula for the capsule shell, whose ingredients are shown on page 97 of your original application.

3. is at present unacceptable as a testing laboratory for the active ingredient, starch, and magnesium stearate. Please indicate your intentions with respect to use of this firm.

The file is now closed. You are required to take one of the actions described at 21 CFR 314.120 which will either amend or withdraw the application, or if you have substantial disagreement with our reasons for not approving this application, you may request an opportunity for a hearing.

Sincerely yours,

9-26

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics

cc:
HFN-237
TPoux/CChang/MGoldman/tr/10/8/86
1032S
Not Approvable

ANDA 89-488

SEP 15 1986

Mutual Pharmaceutical Company, Inc.
Attention: Suhas Sardesai
1100 Orthodox Street
Philadelphia, PA 19124

Dear Mr. Sardesai:

Please refer to your abbreviated new drug application dated May 9, 1986, submitted pursuant to Section 505 of the Federal Food, Drug, and Cosmetic Act for Diphenhydramine Hydrochloride Capsules USP, 25 mg.

Also referenced is your communication of August 26, 1986.

The application is deficient and therefore not approvable under Section 505 of the Act for the following reasons:

1. Your comparative dissolution rate studies and request for bioavailability/bioequivalency waiver is under review by the Division of Bioequivalence. You will be advised when their review is completed.

2. For the Components and Composition sections:

   You must provide a copy of your revised Component section and your revised Composition section showing the following:

   a. The formula for the capsule.

   b. The botanical source of the starch, as required by the NF.

3. For the active ingredient:

   Provide complete name and address for

4. It fails to provide rework (reprocessing) procedures used in the event a batch fails to meet specifications (page 131), as required by 21 CFR 211.115.

The file is now closed. You are required to take one of the actions described at 21 CFR 314.120 which will either amend or withdraw the application, or if you have substantial disagreement with our reasons for not approving this application, you may request an opportunity for a hearing.

Sincerely yours.

c:
HFN-237
TPoux/CChang/MGo[illegible]man/tr/9/11/86
1032S
Not Approvable

/For 9-15-86

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics

FINAL Copy

ANDA 89-488

JUL 31 1986

Mutual Pharmaceutical Company, Inc.
Attention: Suhas Sardesai
1100 Orthodox Street
Philadelphia, PA 19124

Dear Mr. Sardesai:

Reference is made to your abbreviated new drug application submitted pursuant to Section 505 of the Federal Food, Drug, and Cosmetic Act for Diphenhydramine Hydrochloride Capsules USP, 25 mg.

In order for our laboratory to ascertain that your bulk drug conforms to USP requirements, send the following materials to the address below:

Materials to be sent:

1. Bulk active ingredient - Send three times the amount needed to perform all USP testing. Package the material in a tight, moisture - free container sealed in an outer container. Identify the manufacturer, the manufacturer's address, DMF number and lot number of the bulk sent.

2. A Certificate of Analysis (either yours or the manufacturer's) for the lot sent.

3. Standards - Reference, Impurity, and Internal - Send three times the amount required by the USP. [If you do not send the standard and St. Louis doesn't have it, the analysis will be delayed].

4. Copies of representative chromatograms and/or spectra (if applicable.)

Address:

Center for Drugs and Biologics
Office of Drug Research and Review
Room 1002, HFH-300
1114 Market Street
St. Louis, MO 63101
Attention: Mr. Donald Page

These materials must be sent by August 30, 1986. If you cannot send these materials by this date, please notify Mr. Donald Page by letter. If you fail to send the requested materials, or properly notify Mr. Donald Page of any delay, the ANDA file will be closed. Send copies of all correspondence regarding the samples requested to the ANDA.

We recommend that you send the samples by registered mail/return receipt requested.

Sincerely yours,

for 7/31/86

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics

cc:
HFN-237 7/30/86
CChang/MGoldman/tr/7/29/86
0936S
Samples to St. Louis

JUL 31 1986

ANDA 89-488

Mutual Pharmaceutical Company, Inc.
Attention: Suhas Sardesai
1100 Orthodox Street
Philadelphia, PA 19124

Dear Mr. Sardesai:

Reference is made to your abbreviated new drug application submitted pursuant to Section 505 of the Federal Food, Drug, and Cosmetic Act for Diphenhydramine Hydrochloride Capsules USP, 25 mg.

In order for our laboratory to validate your submitted methodology, send the following materials to the address below:

Materials to be sent:

1. Finished dosage form - Send three times the amount needed to perform the required testing. Identify the lot number of the material sent.

2. A Certificate of Analysis for the lot sent.

3. Internal and Reference standards - Send three times the amount necessary to perform the required testing. (If you do not send the standard and the District doesn't have it, the analysis will be delayed).

4. Impurity Standards - send samples of standards for any impurities for which you test the dosage form.

5. Representative chromatograms and/or spectra (if applicable).

Address:

Department of Health and Human Services
Public Health Service
Food and Drug Administration
US Customhouse
Attention: Harvey M. Miller (HFR-3160)
2nd and Chestnut Streets, Room 900
Philadelphia, PA 19106

These materials must be sent by August 30, 1986. If you cannot send these materials by this date, please notify H. Miller by letter. If you fail to send the requested materials or properly notify H. Miller, your ANDA file will be closed. Send copies of all correspondence regarding the samples requested to the ANDA.

We recommend that you send the samples by registered mail/return receipt requested.

Sincerely yours,

FOR 7.31.86

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics

cc:
HFN-237
CChang/MGoldman/tr/7/29/86
0936S
Samples to the District

ANDA 89-488

Mutual Pharmaceutical Company, Inc.
Attention: Suhas Sardesai
1100 Orthodox Street
Philadelphia, PA 19124

JUL 31 1986

Dear Mr. Sardesai:

Please refer to your abbreviated new drug application dated May 9, 1986, submitted pursuant to Section 505 of the Federal Food, Drug, and Cosmetic Act for Diphenhydramine Hydrochloride Capsules USP, 25 mg.

The application is deficient and therefore not approvable under Section 505 of the Act for the following reasons:

1. Your comparative dissolution rate studies and request for bioavailability/bioequivalency waiver is under review by the Division of Bioequivalence. You will be advised when their review is completed.

2. It fails to provide adequate labeling information. In this regard:

   Container: Not Satisfactory

   The quantity is listed as 100 (1000) tablets (rather than capsules).

   Insert: Not Satisfactory
   In accord with very recent changes, please make the following revisions:

   a. CONTRAINDICATIONS-delete heading-"Use in Lower Respiratory Disease" and the first paragraph following.

      Underline the first sentence in the next paragraph <u>Antihistamines also are contraindicated in the following conditions:</u>

   b. PRECAUTIONS-General
      (1) Paragraph one should be changed to read: Diphenhydramine hydrochloride has an atropine-like action and therefore should be used with caution in patients with a history of lower respiratory disease including asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension.

      (2) Drug Interactions-delete <u>CAUTION</u>: Patients taking monoamine oxidase inhibitors should not receive antihistamine therapy concurrently.

   c. DESCRIPTION-structural formula- -N-H-should be in italics.

d. OVERDOSAGE-underline the following phrases at the beginning of paragraphs 2,3,4 and 5:

If vomiting has not occurred spontaneously...
If vomiting is unsuccessful...
Saline cathartics...
Stimulants....

e. DOSAGE AND ADMINISTRATION
Children....three or four times daily....
(rather than three to four).

Please revise your container labels and package insert labeling, then prepare and submit twelve final printed copies of container labels and draft copy of package insert labeling for our review and comment.

3. For the Components and Composition:

Please include the formula for the capsule in these sections, as shown on page 97.

4. For the active ingredient:

Please identify stated as manufacturer on page 78. This name is not otherwise indicated as a source for the active ingredient.

5. For the inactive ingredient:

a. It fails to specify the botanical source of the Starch, NF used.

b. It fails to assure that the Starch, NF meets compendial requirements in that the analytical report (page 87) fails to include tests for pH, Residue on Ignition, Iron, Oxidizing substances, Sulfur dioxide and no Certificate of Analysis from the supplier is provided.

6. For the finished drug product:

It should be understood that the USP procedure will be used as the regulatory method. In this connection provide comparative data showing that the to the USP assay procedure.

The file is now closed. You are required to take one of the actions described at 21 CFR 314.120 which will either amend or withdraw the application, or if you have substantial disagreement with our reasons for not approving this application, you may request an opportunity for a hearing.

Sincerely yours,

7-31-86

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics

cc: 7/30/86
HFN-237 7/30/86
TPoux/CChang/MGoldman/tr/7/29/86
0936S
Not Approvable

ANDA 69-488

MAY 20 1986

Mutual Pharmaceutical Co.
Attention: Mr. Suhas Sardesai
1100 Orthodox Street
Philadelphia, PA 19124

Dear Sir:

We acknowledge the receipt of your abbreviated new drug application submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act for the following:

NAME OF DRUG: Diphenhydramine Hydrochloride Capsules USP, 25 mg

DATE OF APPLICATION: May 9, 1986

DATE OF RECEIPT: May 13, 1986

We will correspond with you further after we have had the opportunity to review the application.

However, in the interim, please submit three additional copies of the analytical methods and descriptive information needed to perform the tests on the samples (both the bulk active ingredient(s) and finished dosage form) and validate the analytical methods. Please do not send samples unless specifically requested to do so. If samples are required for validation we will inform you where to send them in a separate communication.

If the above methodology is not submitted, the review of the application will be delayed.

Please identify any communications concerning this application with the NDA number shown above.

Sincerely yours,

(for 5.20.86

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
Center for Drugs and Biologics

cc: HFN-230
Chang
MSeife/JSturm/jt/5-16-86
Ack 0183b

Mutual Pharmaceutical Company, Inc.

1100 Orthodox Street • Philadelphia, Pennsylvania 19124 • (215) 288-6500

May 9, 1986

Marvin Seife, M.D.
Director
Division of Generic Drug Monographs
Office of Drug Standards
Center for Drugs and Biologics
Food and Drug Administration
HFN 230, Rm 16 - 70
5600 Fishers Lane
Rockville, MD 20857

Re: **Abbreviated New Drug Application**
Product: **Diphenhydramine Hydrochloride Capsules, 25 mg.**

Dear Doctor Seife,

Pursuant to Section 505(j) of the Federal Food Drug and Cosmetic Act, and the Amendments thereto, we are submitting herewith, in duplicate, an abbreviated new drug application for the new drug referred supra.

Included in Section 3 of this application we are respectfully requesting a waiver to conduct bioavailability studies on the dosage form based upon the comparative dissolution rate studies we have conducted on the dosage form of Parke-Davis's Benadryl Capsules 25 mg. Vide: the Orange Section - Pharmacokinetics in Volume No. 2.

Concurrently we are separately filing for the 50 mg potency dosage form of Diphenhydramine Hydrochloride Capsules.

We respectfully submit the following:

a. Form 356-H
b. Volume No. 1 - Copy No. 1 (Blue Folder)
c. Volume No. 2 - ~~Copy No. 1 (Orange Folder)~~ combined
d. Volume No. 1 - Copy No. 2 (Red Folder)
e. Volume No. 2 - Copy No. 2 (Orange Folder)
f. Four (4) sets of labels (drafts)

Yours sincerely,
MUTUAL PHARMACEUTICAL CO., INC.

Suhas Sardesai

SUHAS SARDESAI, M.S.
Director of Operations

RECEIVED
MAY 13 1986
GENERIC DRUGS

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 89488

ADMINISTRATIVE DOCUMENTS

ANDA Approval Summary

89-488 — Mutual Pharm. Co
ANDA Number — Applicant Name

Diphenhydramine HCl — Established Name of Drug
Capsule — Dosage Form
25 mg — Strength
100's 1000's — Container size(s)

	Date Found Satisfactory	Comment
Labeling	12/16/86	
Chemistry, Manufacturing, and Controls	12/16/86	
NP's		
Manufacturer - Finished Dosage Form	12/16/86	
Outside Facilities	12/16/86	
Manufacturer(s) - Active Ingredient(s)	12/16/86	

✓ — Chemist Reviewer — 12/16/86 — Date — Branch Chief — 12-17-86 — Date

Petition Required: X No ___ Yes

Listed Drug Information 505(j)(2)(A)	Acceptable see 5/4/86 Submission	
Ltr Certification 505(j)(2)(A)	"	"
Date Patent/Exclusivity Expires (if applicable)	N/A	

Bioequivalence Section

Dissolution Required? ___ No ✓ Yes : ✓ DB ___ DGD	Acceptable see 12/3/86 Ltr	
In vivo study(s) required? ✓ No ___ Yes (proposed)	THIS IS AN AA drug there is NO IN VIVO requirement	
Study(s) Found Acceptable		
Waiver Request Granted	Waiver Granted see 12/3/86 Ltr	
Total Bioequivalence-Requirement Met	See above	

12/16/86 — Administrative Reviewer — Date

Approved ✓
Disapproved ___

Director, Division of Generic Drugs — 12/18/86 — Date

Remarks:

NG #0479A (Rev-5/85)

NOTICE OF APPROVAL
NEW DRUG APPLICATION OR SUPPLEMENT

NDA NUMBER: 89-488

DATE APPROVAL LETTER ISSUED: JAN 2 1987

TO: Press Relations Staff (HF1-40)

FROM: [X] Bureau of Drugs [ ] Bureau of Veterinary Medicine

ATTENTION

Forward original of this form for publication only after approval letter has been issued and the date of approval has been entered above.

TYPE OF APPLICATION: [ ] ORIGINAL NDA [ ] SUPPLEMENT TO NDA [XX] ABBREVIATED ORIGINAL NDA [ ] SUPPLEMENT TO ANDA

CATEGORY: [XX] HUMAN [ ] VETERINARY

TRADE NAME (or other designated name) AND ESTABLISHED OR NONPROPRIETARY NAME (if any) OF DRUG:
Diphenhydramine Hydrochloride

DOSAGE FORM: Capsule

HOW DISPENSED: [XX] RX [ ] OTC

ACTIVE INGREDIENT(S) (as declared on label. List by established or nonproprietary name(s) and include amount(s), if amount is declared on label.)

Diphenhydramine Hydrochloride, 25 mg

NAME OF APPLICANT (Include City and State)

Mutual Pharmaceutical Co., Inc.
1100 Orthodox Street
Philadelphia, PA 19124

PRINCIPAL INDICATION OR PHARMACOLOGICAL CATEGORY

Antihistamine

COMPLETE FOR VETERINARY ONLY

ANIMAL SPECIES FOR WHICH APPROVED

COMPLETE FOR SUPPLEMENT ONLY

CHANGE APPROVED TO PROVIDE FOR

FORM PREPARED BY

NAME: M. Goldman 12/13/86 DATE: 1/2/87

FORM APPROVED BY

NAME: C. Chang DATE: 1/2/87

FORM FD 1642 (2/75) PREVIOUS EDITION MAY BE USED UNTIL SUPPLY IS EXHAUSTED.

REVIEW OF PROFESSIONAL LABELING

ANDA?DRAFT

DATE OF REVIEW: July 24, 1986

ANDA/NDA#: 89-488 (25 mg)
89-489 (50 mg)

NAME OF FIRM: Mutual

NAME OF DRUG: Generic: Diphenhydramine Hydrochloride Capsules, USP

DATE OF SUBMISSION: May 9, 1986

COMMENTS:

Container: Not Satisfactory

A. The quantity is listed as 100 (1000) tablets (rather than capsules).

Insert: Not Satisfactory
In accord with very recent changes, please make the following revisions:

A. CONTRAINDICATIONS-delete heading-"Use in Lower Respiratory Disease" and the first paragraph following.

Underline the first sentence in the next paragraph <u>Antihistamines also are contraindicated in the following conditions:</u>

B. PRECAUTIONS-General

1. Paragraph one should be changed to read: Diphenhydramine hydrochloride has an atropine-like action and therefore should be used with caution in patients with a history of lower respiratory disease including asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension.

2. Drug Interactions-delete <u>CAUTION</u>: Patients taking monoamine oxidase inhibitors should not receive antihistamine therapy concurrently.

C. DESCRIPTION-structural formula- -N-N-should be in italics

D. OVERDOSAGE-underline the following phrases at the beginning of paragraphs 2,3,4 and 5

If vomiting has not occurred spontaneously...
If vomiting is unsuccessful...
Salene cathartics...
Stimulants....

E. DOSAGE AND ADMINISTRATION
Children....three or four times daily....
(rather than three to four)

RECOMMENDATIONS:

1. Inform the firm of above comments.

2. Request the firm revise their container labels and package insert labeling then prepare and submit twelve final printed copies of container labels and draft copy of package insert labeling for our review and comment.

HFN-238
T.Poux/sw/7-24-86
2458A Pg 4-5

Tom Poux

DEPARTMENT OF HEALTH & HUMAN SERVICES

M. GOLDMAN

Memorandum

TO :Manufacturing Review Branch (HFN-325) DATE: 5/16/86
Division of Drug Quality Compliance

FROM :Division of Generic Drugs
Requester's Name Diane F. Walker PHONE: 443-0193

SUBJECT: ESTABLISHMENT EVALUATION REQUEST

NDA, ANDA, AND SUPPLEMENT NUMBER: 89-488; 89-489

DRUG TRADE MARK (if any)

DRUG NONPROPRIETARY NAME: Diphenhydramine Hydrochloride Capsules USP, 25 mg; 50 mg

DOSAGE FORM AND STRENGTH(S): CHG

DRUG CLASSIFICATION: PROFILE CLASS CODE:
(Priority) _____ A or B _____ 1C _____ Other _____

APPLICANT'S NAME: Mutual Pharmaceutical Co.
ADDRESS: 1100 Orthodox St., Philadelphia, PA

FACILITIES TO BE EVALUATED: (Name, Full Address, DMF# (if any), and Responsibility)

1. applicant - mfr finished dosage form

Co

Reason

****

FOR HFN-325 USE ONLY:

Request Rec'd: 5/16/86 Inspection Requested: _____
(if applicable)

Firm(s) are in Compliance With GMPs: acceptable

Basis for Decision:

Reviewing CSO: 6/24/86 Concurrance: _____

c: HFN-234
HFN-
HFN-325

a

FORM FDA 3274 (1/83)

ANDA ADMINISTRATIVE CONTROL RECORD

Applicant Mutual Pharmaceutical ANDA # 89-458

Date Recd. 5/13/86

Trade Name ____________ RX ✓ OTC ____

Generic Name/Dosage Form/Strength: Diphenhydramine Hydrochloride Capsules USP, 25mg

DESI Drug ____________

Similar or Related ____________

Applicant Manufacturer: Yes ✓ No ____

If No: Name of Manufacturer ____________

ANDA # ________ Approved: ______ Pending ______ Same Formulation ______

Application Complete YES ____ NO ✓

Application Acceptable: YES ✓ NO ____

Needs Analytical Methods? Has Info on First-O Drug

Letter to Firm: Acknowledgement: ✓ Not-acceptable ____ DC Date MAY 20 1986

CSO/CST: ____________ Date 5/16/86

BIO Review Required: YES X NO ____ IN VITRO X IN VIVO ____

Medical Officer ____________

Chemist ____________

Inspection Request to HFD 320 (Date): 5/16/86

7899e/mlb

01-488

ANDA CHECKLIST FOR COMPLETENESS AND ACCEPTABILITY OF THE APPLICATION

	Yes	No
Cover Letter	✓	
356H Signed	✓	
Table of Contents	✓	
Information to show proposed product is same as listed product: (i) indications (ii) active ingredients (iii) (a) route (b) dosage form (c) strength (iv) labeling	✓	
Patent Certification	✓	
Exclusivity Addressed (If Applicable)		
Labeling	Draft	
Statement re Rx/OTC Status	✓	
Components & Composition (Unit Composition)	✓	
Manufacturing Controls	✓	
Batch Formulation	✓	
Certification of GMP	✓	
Description of Facilities	✓	
Manufacturing Procedures (Batch Records)	✓	
Specs & Tests for Active Ingredient and Finished Dosage Form	✓	
Stability Profile Including Stability Data (Use of Stability Indicating Method)	✓	
Samples Statement Plus Data		
Bioavailability/Bioequivalence Protocol		
Study		
In vivo study/waiver request	✓	
Dissolution Data	✓	
Environmental Impact Analysis	✓	

K:jmp:1/3/85:Wang 4528a

DEPARTMENT OF HEALTH & HUMAN SERVICES

M. GOLDMAN

Memorandum

TO :Manufacturing Review Branch (HFN-325) DATE: 5/16/86
Division of Drug Quality Compliance

FROM :Division of Generic Drugs
Requester's Name Diane F. Walker PHONE: 443-0193

SUBJECT: ESTABLISHMENT EVALUATION REQUEST

NDA, ANDA, AND SUPPLEMENT NUMBER: 89-488; 89-489

DRUG TRADE MARK (if any) _____

DRUG NONPROPRIETARY NAME: Diphenhydramine Hydrochloride Capsules USP, 25 mg; 50 mg

DOSAGE FORM AND STRENGTH(S): CHG

DRUG CLASSIFICATION: PROFILE CLASS CODE:
(Priority) _____ A or B _____ 1C _____ Other _____ _____

APPLICANT'S NAME: Mutual Pharmaceutical Co.
ADDRESS: 1100 Orthodox St., Philadelphia, PA

FACILITIES TO BE EVALUATED: (Name, Full Address, DMF# (if any), and Responsibility)

1. applicant - mfr finished dosage form

Cc

Re

****

FOR HFN-325 USE ONLY:

Request Rec'd: 5/16/86 Inspection Requested: _____
(if applicable)

Firm(s) are in Compliance With GMPs: acceptable
Basis for Decision: CI
Reviewing CSO: 6/24/86 Concurrance: _____

cc: HFN-234
HFN-
HFN-325

U

FORM FDA 3274 (1/83)

DEPARTMENT OF HEALTH & HUMAN SERVICES

Memorandum

TO :Manufacturing Review Branch (HFN-322) DATE: 5/16/86
Division of Drug Quality Compliance

FROM :Division of Generic Drugs
Requester's Name Diane F. Walker PHONE: 443-0193

SUBJECT: ESTABLISHMENT EVALUATION REQUEST

NDA, ANDA, AND SUPPLEMENT NUMBER: 89-488; 89-489

DRUG TRADE MARK (if any) _____

DRUG NONPROPRIETARY NAME: Diphenhydramine Hydrochloride Capsules USP, 25 mg; 50 mg

DOSAGE FORM AND STRENGTH(S): CHG

DRUG CLASSIFICATION: PROFILE CLASS CODE:
(Priority) _____ A or B _____ 1C _____ Other _____ _____

APPLICANT'S NAME: Mutual Pharmaceutical Co.
ADDRESS: 1100 Orthodox St., Philadelphia, PA

FACILITIES TO BE EVALUATED: (Name, Full Address, DMF# (if any), and Responsibility)

1. applicant - mfr finished dosage form

cc: 89-131 D. Jarrow

****

FOR HFN-322 USE ONLY:

Request Rec'd: _____ Inspection Requested: _____
(if applicable)

Firm(s) are in Compliance With GMPs: _____
Basis for Decision: _____
Reviewing CSO: _____ Concurrance: _____

cc: HFN-____
HFN-____
HFN-322

FORM FDA 3274 (1/83)

DEPARTMENT OF HEALTH & HUMAN SERVICES

M. GOLDMAN

Memorandum

TO :Manufacturing Review Branch (HFN-325) DATE: 5/16/86
Division of Drug Quality Compliance

FROM :Division of Generic Drugs
Requester's Name Diane F. Walker PHONE: 443-0193

SUBJECT: ESTABLISHMENT EVALUATION REQUEST

NDA, ANDA, AND SUPPLEMENT NUMBER: 89-488; 89-489

DRUG TRADE MARK (if any) _____

DRUG NONPROPRIETARY NAME: Diphenhydramine Hydrochloride Capsules USP, 25 mg; 50 mg

DOSAGE FORM AND STRENGTH(S): CHG

DRUG CLASSIFICATION: PROFILE CLASS CODE:
(Priority) _____ A or B _____ 1C _____ Other _____ _____

APPLICANT'S NAME: Mutual Pharmaceutical Co.
ADDRESS: 1100 Orthodox St., Philadelphia, PA

FACILITIES TO BE EVALUATED: (Name, Full Address, DMF# (if any), and Responsibility)

1. applicant - mfr finished dosage form

-

-

-

A

Comment

Reason: _____

****

FOR HFN-325 USE ONLY:

Request Rec'd: 5/20/86 Inspection Requested: _____
(if applicable)

Firm(s) are in Compliance With GMPs: acceptable
Basis for Decision: _____
Reviewing CSO: _____ 6/24/86 Concurrance: _____

cc: HFN-234
HFN-_____
HFN-325

FORM FDA 3274 (1/83)